Top 10 Treatments proven to Fight COVID-19 (June 2022)
It has added BA.4 and BA.5, sister variants of the original BA.1 Omicron variant, to its list for monitoring. It is already tracking BA.1 and BA.2 - now globally dominant - as well as BA.1.1 and BA.3.
The WHO said it had begun tracking them because of their "additional mutations that need to be further studied to understand their impact on immune escape potential".
For instance, BA.2 now represents nearly 94% of all sequenced cases and is more transmissible than its siblings, but the evidence so far suggests it is no more likely to cause severe disease.
Only a few dozen cases of BA.4 and BA.5 have been reported to the global GISAID database, according to WHO. (Source)
The health watchdog is also keeping a watch on the characteristics and potential benefits of hybrid immunity. Hybrid immunity is defined as immune protection in individuals who have had one or more doses of a Covid-19 vaccine and experienced at least one SARS-CoV-2 infection before or after the initiation of vaccination.
This statement from WHO reflects the current understanding of hybrid immunity and highlights the gaps in evidence and potential implications for vaccination schedules and strategies.
As per WHO, current evidence suggests that immune protection against severe outcomes due to infection and vaccination is more robust than that due to infection, or vaccination alone. This is based on infections with the ancestral SARS-CoV-2 or pre-Omicron VOCs (Variant of Concerns).
|A schematic of the key cellular and biomolecular interactions between Ivermectin, host cell, and SARS-CoV-2 in COVID-19 pathogenesis and prevention of complications.|
Top 10 Treatments proven to Fight COVID-19Irrespective of the type of variant, early treatment is more effective than late treatment or no treatment, as shown in the figure below:
The C19early.com website has continuously updated the evidence-based research on early COVID-19 treatments since June 2020. The website is so exhaustively comprehensive that it could be considered a journal in itself, produced by a team of competent, committed editors.
Although this singular resource has been developed and posted anonymously, one observer commented on Reddit, “It doesn’t really matter who built it, IMO. All studies are referenced/linked.”
The studies for COVID’s readily-available, low-cost, and evidence-based early treatments are divided into sections: Ivermectin, Proxalutamide, Budesonide, Vitamin D, Quercetin, Hydroxychloroquine, Vitamin C, Zinc and many more.
A comprehensive database and global list of COVID-19 treatment studies and outcomes, divided into early treatment and late treatment results, and complete with links and abstracts, is available at this site.
The project has kept up with the recent highly encouraging work on many treatments for COVID-19. Each of these treatment links can be opened to reveal a gold mine of further information.
|Treatment league table|
1. Ivermectin and COVID-19
- Tennessee's legislature made ivermectin essentially an over-the-counter drug. The state’s Senate overwhelmingly voted 66-20, and the House voted 22-6 in favor of the bill (April 2022)
- The TOGETHER Trial Was Designed to Fail (April 2022)
- Ivermectin has a number of potentially serious drug-drug interactions. Please check for potential drug interaction at Ivermectin Drug Interactions - Drugs.com. The most important drug interactions occur with cyclosporin, tacrolimus, anti-retroviral drugs, and certain anti-fungal drugs.
- Ivermectin is also lipophilic and therefore, bioavailability is maximised on a full stomach; or best to be taken with meal.
2. Dietary Supplements (Vitamin D, C, Black Seed Oil, Zinc, Quercetin, Vitamin A and Melatonin) and COVID-19Based on the AAPS (Association of American Physicians and Surgeons) algorithm or flowchart below, nutraceuticals are the first line treatment for mild COVID-19 patients.
3. Paxlovid and COVID-19
U.S. health regulators authorized the first oral pill against COVID-19 in December 2021 (Associated Press), a Pfizer drug that Americans will be able to take at home to head off the worst effects of the virus.
Authorization was based on results from EPIC-HR, a randomized, placebo-controlled treatment trial in adult outpatients with mild-to-moderate COVID who were at high risk for progression to severe disease.
The latest (last updated: April 8, 2022) NIH guidelines recommended Paxlovid as the no. 1 preferred therapy for non-hospitalized patients.
|Treatment league table|
The Food and Drug Administration authorized Pfizer’s drug for adults and children ages 12 and older with a positive COVID-19 test and early symptoms who face the highest risks of hospitalization. That includes older people and those with conditions like obesity and heart disease. Children eligible for the drug must weigh at least 88 pounds (40 kilograms).
The pills from both Pfizer and Merck are expected to be effective against omicron because they don’t target the spike protein where most of the variant’s worrisome mutations reside.
Pfizer currently has 180,000 treatment courses available worldwide, with roughly 60,000 to 70,000 allocated to the U.S. Federal health officials are expected to ration early shipments to the hardest hit parts of the country. Pfizer said the small supply is due to the manufacturing time — currently about nine months. The company says it can halve production time next year.
The U.S. government has agreed to purchase enough Paxlovid to treat 10 million people. Pfizer says it’s on track to produce 80 million courses globally next year, under contracts with the U.K., Australia and other nations.
Health experts agree that vaccination remains the best way to protect against COVID-19. But with roughly 40 million American adults still unvaccinated, effective drugs will be critical to blunting the current and future waves of infection.
Against that backdrop, experts warn that Paxlovid’s initial impact could be limited.
For more than a year, biotech-engineered antibody drugs have been the go-to treatments for COVID-19. But they are expensive, hard to produce and require an injection or infusion, typically given at a hospital or clinic. Also, laboratory testing suggests the two leading antibody drugs (from Regeneron and Eli Lilly) used in the U.S. aren’t effective against omicron.
Pfizer’s pill comes with its own challenges.
Patients will need a positive COVID-19 test to get a prescription. And Paxlovid has only proven effective if given within five days of symptoms appearing. With testing supplies stretched, experts worry it may be unrealistic for patients to self-diagnose, get tested, see a physician and pick up a prescription within that narrow window.
“If you go outside that window of time I fully expect the effectiveness of this drug is going to fall,” said Andrew Pekosz, a Johns Hopkins University virologist.
The FDA based its decision on company results from a 2,250-patient trial that showed the pill cut hospitalizations and deaths by 89% when given to people with mild-to-moderate COVID-19 within three days of symptoms. Less than 1% of patients taking the drug were hospitalized and none died at the end of the 30-day study period, compared with 6.5% of patients hospitalized in the group getting a dummy pill, which included nine deaths.
How much will Paxlovid cost?
The COVID-19 Treatment Guidelines Panel’s Statement on Therapies for High-Risk, Nonhospitalized Patients With Mild to Moderate COVID-19 (Last Updated: April 8, 2022)
The Panel’s recommendations take into account the efficacies of these drugs and the high prevalence of the Omicron VOC. When resources are limited, therapy should be prioritized for patients who are at the highest risk of progressing to severe COVID-19.
The Panel’s current outpatient treatment recommendations are as follows (in order of preference):
- Paxlovid (nirmatrelvir 300 mg plus ritonavir 100 mg) orally twice daily for 5 days
- Remdesivir 200 mg IV on Day 1 followed by remdesivir 100 mg IV on Days 2 and 3
- Bebtelovimab (monoclonal antibody from Eli Lilly)
- Molnupiravir 800 mg orally twice daily for 5 days
- Bebtelovimab is active in vitro against all circulating Omicron subvariants, but there are no clinical efficacy data from placebo-controlled trials that evaluated the use of bebtelovimab in patients who are at high risk of progressing to severe COVID-19. Therefore, bebtelovimab should be used only when the preferred treatment options are not available, feasible to use, or clinically appropriate.
- According to GoodRx Health (Jan 26, 2022): Studies suggest that Paxlovid can lower the risk of severe COVID-19 for high-risk people by almost 90%. Studies suggest molnupiravir can lower this risk by about 30% in high risk people.
New Paxlovid Dose Pack Authorized by FDA
- The standard packaging that is currently in distribution: 300 mg nirmatrelvir;100 mg ritonavir - Each carton contains 30 tablets divided in 5 daily-dose blister cards. Each blister card contains 4 nirmatrelvir tablets (150 mg each) and 2 ritonavir tablets (100 mg each). Nirmatrelvir tablets and ritonavir tablets are supplied in separate blister cavities within the same child-resistant blister card.
- The new packaging option that will be in distribution later this month: 150 mg nirmatrelvir; 100 mg ritonavir - Each carton contains 20 tablets divided in 5 daily-dose blister cards. Each blister card contains 2 nirmatrelvir tablets (150 mg each) and 2 ritonavir tablets (100 mg each). Nirmatrelvir tablets and ritonavir tablets are supplied in separate blister cavities within the same child-resistant blister card.
4. Hydroxychloroquine and COVID-19
Hydroxychloroquine, developed in the 1950s from chloroquine, an old anti-malarial drug, is registered in around 60 countries under trade names such as Plaquenil, Quensyl and Plaquinol.
- Ivermectin: 0.4–0.6 mg/kg per dose (take with or after meals) — one dose daily, take for 5 days or until recovered. (Find a Doctor). Use upper dose range if: 1) in regions with more aggressive variants (e.g. Delta); 2) treatment started on or after day 5 of symptoms or in pulmonary phase; or 3) multiple comorbidities/risk factors. (Ref)
- Hydroxychloroquine (preferred for Omicron): 200mg PO twice daily; take for 5 days or until recovered. (Find a Doctor)
Most of the other component treatments in the I-MASK+ protocol have various mode of actions and may not be affected by the changes in the Omicron variant spike protein.
5. Povidone Iodine and Mouthwash
Due to the presence of angiotensin-converting enzyme 2 (ACE2) in the oral gingival epithelium and salivary glands, the human oral cavity may act as a reservoir for SARS-CoV-2. The ACE2 present on the host cell membrane acts as the primary entry receptor for SARS-CoV-2. Evidence indicates that the saliva of SARS-CoV-2-infected individuals contains high amounts of viral RNA and that aerosols formed from the saliva can act as a potential vector for viral transmission.
Povidone iodine (PVP-I) is an antiseptic that has been used for over 150 years. It's already proven that different concentration of PVP-I can deactivate COVID-19 virus.
In a pilot primary prevention study in Singapore, a povidone-iodine throat spray administered three times daily proved to be highly effective in reducing the risk of laboratory confirmed SARS-CoV-2 infection.
6. Curcumin and Turmeric - Anti-inflammatory and anti-viral
Curcumin, a yellow carotenoid from turmeric, is well known for its
anti-inflammatory and free radical-scavenging effects.
There are more than 15 studies of curcumin in COVID-19 published. And the results are
Curcumin also acts as natural zinc ionophores and can promote the
cellular uptake of zinc and can be used with zinc to increase the
effectiveness of these compounds in the inhibition of the virus (Ref).
Curcumin has been demonstrated (Ref) to suppress several inflammatory cytokines and mediators of their
release such as tumor necrosis factor-alpha (TNF-alpha), IL-1, IL-8
and nitric oxide synthase.
7. NAC and Glutathione - Anti-inflammatory and anti-coagulantN-acetylcysteine (NAC) is a precursor to glutathione. It is an antioxidant and increases glutathione levels in the body (Source). NAC has mucolytic activity, so it helps reduce respiratory mucus levels. Laboratory research suggests that NAC might boost immune system function and suppress viral replication. NAC also decreases levels of interleukin-6 and has other anti-inflammatory effects.
- On April 21, 2022 US FDA announced the issuance of draft guidance on FDA’s policy regarding dietary supplements containing N-acetyl cysteine (NAC). The guidance details the agency’s intent to exercise enforcement discretion on the sale and distribution of such products.
- In 2020 FDA sent warning letters to several companies regarding the use of NAC in dietary supplements. In the letters, FDA warned against the use of drug claims, but also noted that NAC could not be marketed as a dietary supplement because there was no evidence that NAC had been marketed as a food or dietary supplement prior to its approval as a drug in 1963. More recently, we reported that FDA had confirmed in response to citizen petitions that NAC is excluded from the definition of a dietary supplement. FDA had not yet reached a decision, however, regarding a petitioner’s request to issue a regulation that would permit the use of NAC in dietary supplements.
8. Probiotics - Anti-inflammatory
You can find a list of 16 published clinical studies (7 RCTs) on probiotics and COVID-19 from c19probiotics.com (constantly updated).
9. Lactoferrin - Anti-viral
Lactoferrin may slow pathogen multiplication through its iron binding capacity. While iron is required for DNA replication and energy production, the presence of excess iron increases free radical generation, stimulates inflammatory processes, and exacerbates viral infection by promoting increased viral replication (Ref). Furthermore, patients with a severe acute viral respiratory infection have been found to have elevated levels of ferritin, and these levels correlated with increased risk of death (Ref). In its iron-free state (apolactoferrin), lactoferrin can sequester pro-oxidant free iron, lowering oxidative stress and suppressing the growth of pathogens, and possibly mitigating the serious complications of infection (Ref).
10. Other Potential Treatments
For a list of COVID-19 early treatment studies, check out c19early.com (constantly updated).
Summary of Early Treatment Studies (including cost)
|Summary of Early Treatment Studies (including cost)|
Quercetin, Vitamin C, D, Zinc, Black Seed Oil, Melatonin and the FLCCC Protocol
So how do we combine multiple treatments together? Most of the
treatments above are part of the FLCCC I-MASK+ prevention and early
For updated prevention and early outpatient protocol for COVID-19 positive, please check out FLCCC I-MASK+ protocol.
Most of the treatments above are also part of the Zelenko Protocol. In an effort to make it easier for patients, Dr Zelenko has
developed an oral supplement that contains all four key
ingredients: vitamin C, quercetin, vitamin D3 and zinc. It’s
referred to as 'Z-Stack Supplement'.
Take Home MessageIn summary, when used early and in combination; all these treatments can be a true game-changer when it comes to fighting COVID-19.
The combination of nutraceuticals alone i.e. quercetin, zinc, vitamin D, vitamin C, black seed oil and melatonin offer a high virus inhibiting and anti-inflammatory potential with a valuable degree of safety at a time of great uncertainty.
Quercetin, zinc, vitamin D and C are part of the FLCCC I-MASK+ protocol and Zelenko Protocol.
However, if your risk is high e.g. age above 60, hypertensive,
diabetic and obese; you might wish to consult a doctor and
discuss more potent alternatives in the FLCCC
Keep in mind that you should never attempt to self medicate without
the guidance of a licensed medical provider. If you are not a
medical doctor, you are likely to find the information above
Please also follow other precautions and measures (as advised by your
local health authorities and doctors) in order to minimize your risk.
Treatments do not replace vaccines and other measures. All practical,
effective, and safe means should be used. Elimination is a race against
viral evolution. No treatment, vaccine, or intervention is 100%
available and effective for all variants.
In an effort to make it easier for patients, Dr Zelenko has developed an oral supplement that contains all four key ingredients: vitamin C, quercetin, vitamin D3 and zinc. It’s referred to as 'Z-Stack Supplement'.
Z-Stack Vitamin cocktail provides key ingredients needed in order to help your body fight off this deadly invader. The Z-Stack Vitamins are Kosher certified, GMP certified and made in the USA.
Note: To get 5% OFF, please use this coupon code: DRFRANCIS
Post a Comment